Ortho Clinical Diagnostics Named Trailblazer 2018 Company of the Year by PM360
Recognized as One of the Most Influential Companies in the Medical Device/Diagnostic Category
RARITAN, N.J., Sept. 14, 2018 /PRNewswire/ -- Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, has been named the Trailblazer 2018 Company of the Year in the Medical Device/Diagnostics Category by PM360, a respected publication for marketing decision-makers in the pharmaceutical, biotech and medical device industries. This recognition, selected by the PM360 Editorial Advisory Board, recognizes companies that have made a significant impact in the health care industry through achievements in innovation, social responsibility and talent development.
"Since becoming an independent company in 2014, Ortho has steadily grown revenues and installed customer base, all while delivering dozens of products that improve lab operations and enable new diagnostic insights," said Martin Madaus, chairman and CEO of Ortho Clinical Diagnostics. "This recognition from PM360 is an honor for all the employees who have worked hard to grow the company while serving the needs of our customers."
Innovation:
Since the 2014 carve-out from its former parent company, Ortho has achieved steady, year-over-year growth, while delivering critical new products for the clinical labs and immunohematology communities. Among recent key launches: Ortho's VITROS® XT 7600 Integrated System, a next-generation clinical lab analyzer that brings digital chemistry to diagnostics; and ORTHO VISION® Platform, the first fully automated portfolio of immunohematology instruments, which analyze blood for use in transfusion. The company is on track to deliver more than 60 new or enhanced assays from 2014 to 2018.
Ortho is equally committed to innovation in customer service and support. The award-winning, top-ranked Ortho Care™ program employs remote monitoring, predictive analytics and e-connectivity functionality to maximize uptime and reliability of Ortho technology installed in customer sites around the world.
Social Responsibility:
Ortho has helped to significantly reduce the environmental footprint of its customers around the world, because Ortho's proprietary dry slide technology does not require water or drains to operate. In contrast, the systems of other in vitro diagnostics companies use enough water to fill thousands, even millions, of 8-ounce water bottles. Ortho is the only global provider of dry slide technology.
Ortho is just as determined to support sustainability at its own sites. The company's global headquarters in Raritan, N.J., is recognized as an Environmental Stewardship Site by the New Jersey Department of Environmental Protection. Ortho's global center of excellence for R&D in Rochester, N.Y., is a member of the New York Green Business Program (formerly the NYSDEC Environmental Leaders Program), one of only 14 companies in New York certified as a charter member of the program, which recognizes superior environmental performance. Worldwide, Ortho reduced landfill waste by 17 percent from 2015 to 2017, and achieved a zero landfill status at its Pencoed, Wales facility in 2016 and 2017.
Talent Development:
Ortho shaped a distinct culture that emphasizes talent management and the company's commitment to customers. The results illustrate a great place to work: ninety-eight percent of legacy employees followed Ortho into independence and more than 2,200 employees have joined the company since 2014. In addition, Ortho was recognized as a Great Place To Work® in India earlier this year.
"As a winner of the medical device and diagnostics category, Ortho demonstrated incredible work in delivering innovation, social responsibility and talent development in one of the most critical sectors of the health care industry," said Anna Stashower, CEO and Publisher of PM360. "Ortho is on the frontlines and leading the charge in diagnostics. We are proud to honor and put the spotlight on this innovative organization."
Ortho Clinical Diagnostics was honored during a special reception at Gotham Hall in New York City on Thursday, September 13, 2018.
About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com.
CONTACT: Joseph Contrino, Ortho Clinical Diagnostics, T: +1 908 210 1076, joseph.contrino@orthoclinicaldiagnostics.com
